-- Alteogen (KOSDAQ:196170) posted first-quarter net income attributable to shareholders of 71.7 billion won, down 14% from 83.2 billion won a year earlier, according to a Friday filing with the Korea Exchange.
Sales of the South Korean pharmaceutical firm fell 15% year over year to 71.6 billion won from 83.7 billion won.
Shares of Alteogen fell over 4% at market close.
Anhui Fengyuan Pharmaceutical (SHE:000153) obtained drug registration from China's medical products regulator for its compound polyethylene glycol and electrolytes powder.The prescription powder is indicated for treating chronic constipation in children, according to a Friday filing with the Shenzhen bourse.The approval is valid until April 28, 2031.Shares of the company closed 1% higher Friday.
Shukra Pharmaceuticals (BOM:524632) booked a consolidated net loss of 17.2 million Indian rupees in the fiscal fourth quarter ended March 31 against a profit of 53.9 million rupees a year earlier.Shares of the company fell 5% in recent trade.Loss per share stood at 0.04 rupees compared with earnings per share of 0.12 rupees a year ago, according to a Thursday filing to the Indian stock exchanges.Net sales in fiscal Q4 slipped to 63.2 million rupees from 132.7 million rupees a year prior.
RailTel Corporation of India (NSE:RAILTEL, BOM:543265) secured an order worth 249.1 million Indian rupees from The New India Assurance Company, according to a filing to the Indian stock exchanges.The contract is for the procurement of an artificial intelligence and machine learning-based solution for monitoring and investigation of fraud, waste, and abuse of health insurance claims.The order will be executed by May 6, 2029.The company's shares were down over 1% in recent trade.